Key result
Pharmacotherapy for PDA presents varying risks and benefits in extremely premature neonates.
Why the study?
What are the current options, benefits, and risks of pharmacotherapy for patent ductus arteriosus in extremely premature neonates?
Population
Extremely premature neonates with patent ductus arteriosus (PDA)
Design
Review
Authors
Loading...
Pharmacotherapy choices for PDA in extremely premature neonates require individualized risk-benefit assessment; leaves open acetaminophen's role pending randomized trials.
What are the current options, benefits, and risks of pharmacotherapy for patent ductus arteriosus in extremely premature neonates?
This review highlights the efficacy and adverse effect profiles of current pharmacotherapies for PDA in premature neonates, noting acetaminophen as a promising alternative requiring further study.
Rostas et al. (2016) conducted a review in Patent ductus arteriosus. Pharmacotherapy (indomethacin, ibuprofen, acetaminophen) was evaluated. Pharmacotherapy options for patent ductus arteriosus, including indomethacin, ibuprofen, and acetaminophen, present varying risks and benefits for extremely premature neonates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: